Immunotherapy in Lung Cancer
The treatment of patients with good performance status and advanced stage non–small cell lung cancer has been based on the use of first-line platinum-based doublet and second-line docetaxel. Immunotherapy represents…
New Targets in Non–Small Cell Lung Cancer
With the implementation of genomic technologies into clinical practice, we have examples of the predictive benefit of targeted therapy for oncogene-addicted cancer and identified molecular dependencies in non–small cell lung…
Diagnosis and Treatment of Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer
Anaplastic lymphoma kinase ( ALK ) gene rearrangements occur in a small portion of patients with non–small cell lung cancer (NSCLC). These gene rearrangements lead to constitutive activation of the…
Second-Line Chemotherapy and Beyond for Non–Small Cell Lung Cancer
The landscape for the second- and third-line treatment of advanced non–small cell lung cancer has changed dramatically over the last two decades. Immunotherapeutic agents have become a preferred choice following…
Epidermal Growth Factor Receptor Mutated Advanced Non–Small Cell Lung Cancer
Activating mutations in the epidermal growth factor receptor (EGFR) are present in approximately 15% of US patients with lung adenocarcinoma. EGFR tyrosine kinase inhibitors are associated with high response rate…
First-Line Systemic Therapy for Non–Small Cell Lung Cancer
Major advances in the treatment of metastatic non–small cell lung cancer have led to significant incremental improvements in patient outcomes. Platinum-based combination therapy remains the cornerstone of first-line therapy. The…
Treatment of Locally Advanced Non–Small Cell Lung Cancer
Locally advanced non–small cell lung cancer is a heterogeneous disease with typically poor outcomes. Select patients may benefit from the integration of surgery, whereas patients with bulky, multistation, or contralateral…
Lung Cancer Biomarkers
The molecular characterization of lung cancer has changed the classification and treatment of these tumors, becoming an essential component of pathologic diagnosis and oncologic therapy decisions. Through the recognition of…
Neoadjuvant and Adjuvant Therapy for Non–Small Cell Lung Cancer
The use of 4 cycles of cisplatin-based adjuvant chemotherapy is now the standard of care for patients with resected stage II and IIIA non–small cell lung cancer. Neoadjuvant chemotherapy lacks…
Next-Generation Sequencing of Lung Cancers
Targeted therapies and immune checkpoint inhibitors have significantly improved outcomes in a sizable fraction of patients with metastatic non-small cell lung cancer. Nevertheless, a majority of patients with lung cancer…
